Sylvie Glaisner

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

Philippe Rousselot, marie Magdelaine Coude, Nicola Gökbuget et al. · Blood · 2016 · 326 citations · Full text

Medicine, Hematology, Oncology +9

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Emmanuel Bachy, John F. Seymour, Pierre Feugier et al. · Journal of Clinical Oncology · 2019 · 278 citations · Full text

Medicine, Immunology, Oncology +10

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Philippe Moreau, Cyrille Hulin, Margaret Macro et al. · Blood · 2016 · 276 citations · Full text

Medicine, Oncology, Hematologic Oncology +8

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial

Franck Morschhauser, Olivier Fitoussi, Corinne Haïoun et al. · European Journal of Cancer · 2013 · 131 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients

Ludovic Nguyen-Them, Myrto Costopoulos, Marie‐Laure Tanguy et al. · European Journal of Cancer · 2016 · 100 citations

Medicine, Immunology, Oncology +14